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Abstract 
Background: Peri-procedural major bleeding complications following PCI are associated 
with increased morbidity and mortality outcomes although the influence of site-specific 
major bleeding complications following PCI on prognostic outcomes has yielded conflicting 
data. The object of this study is to provide an overview of site-specific major bleeding events 
in contemporary PCI, and systematically study the association of site-specific major bleeding 
complications following PCI and mortality and MACE outcomes.  
Methods and Results: We conducted a systematic review and meta-analysis of PCI studies 
that evaluated site-specific peri-procedural bleeding complications and their impact on 
MACEs and mortality outcomes. A systematic search of MEDLINE and EMBASE was 
conducted to identify relevant studies and random effects meta-analysis was used to estimate 
the risk of adverse outcomes with site-specific bleeding complications.  25 relevant studies 
including 2,400,645 patients that underwent PCI were identified. Both non-access site (RR 
4.06 95% CI 3.21-5.14) and access site (RR 1.71 95% CI 1.37-2.13) related bleeding 
complications were independently associated with an increased risk of peri-procedural 
mortality. There were differences in the prognostic impact of non-access site related bleeding 
events on mortality outcomes according to the source of anatomical bleeding, for example 
gastrointestinal RR 2.78 95% CI 1.25-6.18, retroperitoneal RR 5.87 95% CI 1.63-21.12, 
intracranial RR 22.71 95% CI 12.53-41.15. 
Conclusions: Site-specific bleeding complications following PCI are independently 
associated with an increased risk of mortality, although the prognostic impact varies 
according to anatomical source. Non-access site related bleeding complications have a 
similar prevalence to those derived from the access site but are associated with a significantly 
worse prognosis. 
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Introduction 
 Major bleeding is one of the most common complications following percutaneous 
coronary intervention (PCI) and is independently associated with a 3-fold increase in 
mortality and major adverse cardiovascular events (MACE)1 and contribute up to 12.1% of 
all in-hospital mortalities following PCI.2   
 There are currently around 10 different definitions of major bleeding used in trials and 
registries of patients undergoing PCI with these definitions including clinical events, such as 
blood transfusion or retroperitoneal hemorrhage, laboratory parameters such as decreases in 
hemoglobin and clinical outcomes such as mortality.3 Such major bleeding events as defined 
by different contemporary bleeding definitions have different impacts on mortality outcomes 
dependent on the definition of major bleeding used that may relate to the different prognostic 
impact of the different components that make up each individual bleeding definition.1  
 Major bleeding complications occur at several sites such as the arterial access site (in 
particular the femoral artery), or from non-access site sources such as intracranial, 
gastrointestinal tract or retro-peritoneum. However, previous studies have reported 
conflicting data regarding both the prevalence of access and non-access site related bleeding 
complications4-7 and their relative prognostic impacts.4-6, 8-11 
 To date there has not been a systematic review or meta-analysis published studying 
the prevalence or prognostic impact of site-specific bleeding complications following PCI. In 
this meta-analysis, we provide an overview of the cohorts evaluating the rates of site-specific 
major bleeding events in studies reporting PCI outcomes, and systematically study the 
association of site-specific major bleeding complications following PCI and mortality and 
MACE outcomes.  
 
Methods 
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Eligibility criteria 
 We selected studies that studied the impact of site-specific bleeding complications on 
mortality or major adverse cardiovascular events (MACE) in patients who underwent PCI.  
Site-specific bleeding complications included: intra-myocardial, pericardial, cardiac 
tamponade, gastrointestinal, retroperitoneal, intracranial, femoral, access site or non-access 
site bleeding complications. 
 
Search strategy 
 A search of EMBASE (1974 to March 2014) and MEDLINE (1946 to March 2014) 
was conducted on OVID SP.  The search terms are shown in Supplemental Table 1.  We 
checked the bibliographies of included studies and relevant review articles found on the 
search for additional relevant articles. 
 
Study selection and data extraction 
 Two reviewers (CSK and MAK) checked all titles and abstracts for studies that could 
potentially meet the inclusion criteria.  We retrieved full reports of potentially eligible studies 
and independently extracted relevant data on study design, participant characteristics, 
bleeding and outcome events, onto a preformatted spreadsheet. Any discrepancies between 
the two reviewers were resolved by consensus after consulting another reviewer (MAM or 
YKL).  
 
Quality assessment 
 Risk of bias was assessed by considering four different areas: ascertainment of 
bleeding events, ascertainment of outcome events, extent of loss to follow up and the use of 
adjustment for confounders in the analysis.  We also assess for publication bias using funnel 
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plots when there were>10 studies available in the meta-analysis and there was no evidence of 
substantial statistical heterogeneity.12 
 
Data analysis 
 We used RevMan 5.1.7 (Nordic Cochrane Centre) to undertake random effects meta-
analysis using the inverse variance methods for pooled risk ratios.   We assumed similarity 
between the risk ratio, and other relative measures such as odds ratio, relative risk, rate ratios 
or hazard ratios because cardiovascular events and death were rare events.13 Where there 
were enough studies, the analysis was stratified based on whether the results had considered 
the effect of potential confounders through adjustments or propensity matched cohorts or not. 
In order to reduce the risk of bias from confounders, we appraised studies with multivariate 
adjustments or propensity matched cohorts separately from studies with crude or unadjusted 
results. For datasets reporting multiple time-points, we took the earliest time-point for the 
primary analysis.   We performed sensitivity analysis only including randomized controlled 
trials, considering the effect of anticoagulation and stratifying the analysis of access and non-
access site bleeding by indication for PCI. We used the I2 statistic to assess statistical 
heterogeneity.  I2 values of 30% to 60% represent moderate levels of heterogeneity.  Where 
there was a high degree of heterogeneity and sufficient number of studies (more than five) in 
an analysis we performed sensitivity analysis by considering subgroups. 
 
Results 
Study selection 
 The process of study selection is shown in Supplemental Figure 1.  We retrieved 25 
relevant studies of patients that underwent PCI (total number of subjects 2,400,645), which 
evaluated the risk of adverse events with and without major bleeding.2, 4-11, 14-29 Excluded 
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studies are shown in Supplemental Table 2.  The patient cohort size ranged from 73 to 
1,216,759 and 106,490 major bleeding events were recorded (23 studies, 4.5%). 22 studies 
evaluated mortality as an outcome2, 6, 8-11, 14, 16-21 and 9 studies reported on major adverse 
cardiovascular events.5, 7, 14, 15, 19, 23, 25-27 
 
Description of studies included 
 Study design, date of study, country of origin and indication for PCI is shown in 
Table 1. The age and gender of participants along with the anti-platelet and anti-coagulant 
regimens are shown in Supplemental Table 3.  The extent to which femoral access site was 
used in the include studies is shown in Supplemental Table 4. Supplementary Table 5 
illustrates baseline co-variates and procedural demographics that have been adjusted for in 
each analysis. At total of 13 studies reported the type of access site with a total of 398,903 
participants.  Among these studies there were 8,097 radial (2%) and 390,806 femoral  (98%). 
 
Quality assessment 
 Supplemental Table 6 shows the quality assessment for included studies. Most studies 
did not report loss to follow up (n=15)6, 9-11, 15, 17-20, 22-26, 29 and 10 studies did not adjust for 
potential confounders.9, 11, 16-18, 20, 23, 25-27 
 
Site-specific bleeding and risk of adverse events 
 Description of the incidence, type and outcomes of major bleeding events are shown 
in Table 2.  Out of the 25 included studies, 7 evaluated access site bleeding complications2, 4-7, 
20, 28 and 6 evaluated non-access site bleeding complications,2, 4-7, 20 . Other site specific 
bleeding complications and their associated outcomes are shown in Table 3. 
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Access and non-access site bleeding 
 There were 7 studies2, 4-7, 20, 28 that evaluated adverse outcomes (either mortality or 
MACE) with access site related bleeding complications (33,677 bleeding events in 301,404 
patients, prevalence 11.2%) and 6 studies2, 4-7, 20 that evaluated non-access bleeding (29,600 
bleeding events in 290,456 patients, prevalence 10.2%). Five studies evaluated mortality 
endpoints2, 4, 6, 20, 28, the crude mortality rate was 2.8 % (906/31795) in patients who 
experienced an access site bleed compared to 1.9 % (5001/261676) in the remaining cohort. 
The crude mortality rate for studies 2, 4, 6, 20 reporting non-access related bleeding 
complication was 8.3% (2203/26530) vs 1.9% (4923/255140) in the remaining cohort. All 
studies reported either adjusted estimates or propensity matched cohort data for use in our 
meta-analysis. The pooled results of 5 studies suggests that the mortality was higher with 
non-access site bleeding (RR 4.06 95% CI 3.21-5.14, 4 studies) compared to access site 
bleeding (RR 1.71 95% CI 1.37-2.13, 5 studies) (Figure 1).  Only one study reported the risk 
of MACE5 with access and non-access site bleeding and the risks were HR 0.74 95% CI 
0.16-3.4 and HR 2.66 95% CI 1.21-5.8, respectively. One other study,7 reported the 
composite outcome of death and MI and the risk estimate for this composite outcome was not 
statistically significant for access site bleeding (RR 1.83 95% CI 0.5-6.61) but was significant 
for non-access site bleeding (RR 2.45 95% CI 1.48-4.04).  The pooled risk of adverse 
outcomes (mortality, mortality and myocardial infarction and MACE) was higher with non-
access site bleeding (RR 3.70 95% CI 2.92-4.69, 6 studies) compared to access site bleeding 
(RR 1.65 95% CI 1.37-1.99, 7 studies) (Supplementary Figure 2). These results are 
summarized in Table 3. Two studies8, 27 specifically evaluated the risk of mortality with 
isolated femoral bleeding complications and there was no significant difference when the 
results were pooled (RR 2.17 95% CI 0.07-69.22, 2 studies, 103 bleeds, 3,239 no bleeds).   
 
9 
 
Gastrointestinal bleed 
 Figure 2 and 3 shows the risk of mortality and MACE considering unadjusted and 
adjusted results separately.  Eight of the ten studies reported crude mortality rate6, 10, 14, 16-19, 21 
which was 13% in patients experiencing a GI bleed (96/738), and 3% in the remaining cohort 
(1898/55771). There was a significant risk of mortality with GI bleeding which was lower 
after adjustment (adjusted RR 2.78 95% CI 1.25-6.18 vs unadjusted RR 6.39 95%CI 4.58-
8.91) from ten studies6, 10, 14, 16-19, 21, 22, 29,  MACE was considered in 4 studies14, 19, 21, 23.  The 
crude rate of MACE with and without GI bleed was 22% (92/417) and 11% (4360/39412) 
respectively.  The risk of MACE was significantly higher in those patients who experienced a 
GI bleed for the unadjusted studies (RR 2.25 95% CI 1.66-3.05) but not in the adjusted 
studies (RR 1.23 95% CI 0.55-3.05).   
 
Retroperitoneal, intracranial and femoral bleed 
 Five studies6, 8, 9, 11, 26 evaluated 696 retroperitoneal bleeds in 153,489 patients 
(0.45%) (Table 3).  The crude mortality rate in 4 studies 6, 9, 11, 26 was 6.8% in the group who 
experienced a retroperitoneal bleed (47/696) and 1.6% in the remaining cohort 
(2377/152793).  Retroperitoneal bleeding was associated with a significant increase risk of 
mortality (RR 5.87 95% CI 1.63-21.12, 5 studies, Figure 4). Two studies10,28 evaluated the 
risk of mortality with femoral bleeding and the pooled result showed a trend towards an 
increase in mortality (OR 2.17 95% CI 0.07-69.22) that was not significant.  Intracranial 
bleeds were evaluated in 1 study6 that reported 5 deaths in 9 patients who experienced an 
intracranial bleed and 310 deaths in the remaining 12,670 cohort.  The risk ratio for mortality 
following an intracranial bleed was RR 22.71 95% CI 12.53-41.15.  
 
Intra-myocardial bleed, pericardial bleed and cardiac tamponade 
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 A total of four studies evaluated intramyocardial bleeds, pericardial bleeds and 
cardiac tamponade.6, 15, 24, 25(Table 3) Three of the four studies6, 24, 25 reported crude mortality 
rates of 8.6% (19/222) in those experiencing a bleed and 2.4% (319/12890) in the remaining 
group of patients.  One study 25 reported the crude rate of MACE of 13.3% (19/143) with 
intra-myocardial bleeding, compared to 12.1% (21/173) without. There was no significant 
difference in adverse outcomes (mortality or MACE) with intramyocardial bleeding (RR 1.65 
95% CI 0.66-4.13, 2 studies, 154 bleeds, 276 no bleeds) but there were significant increases 
in mortality with pericardial bleeding (RR 7.71 95% CI 4.37-13.61, 1 study, 53 bleeds, 
12,670 no bleed) and cardiac tamponade with coronary perforation (RR 3.30 95% CI 1.02-
10.72, 1 study, 26 bleeds, 47 no bleeds).   The pooled results of all these studies show that 
adverse outcomes (mortality or MACE) are increased with intra-myocardial and pericardial 
bleeding complications (RR 2.96 95% CI 1.07-8.17, 4 studies with 233 bleeds, 12,993 no 
bleeds) (Figure 5). 
 
Sensitivity analysis only including randomized controlled trials, effect of indication and 
studies that have adjusted for anti-coagulaton regime. 
 
Sensitivity analysis only including randomized controlled trials is shown in Supplementary 
Table 7.  In general, there were similar estimates for risk of adverse outcomes with access 
site, non-access site and gastrointestinal bleeding in randomized controlled trials and when all 
studies were included.  Similarly studies that have adjusted for anti-coagulant choice show 
worse outcomes associated with non-access site bleeds (Supplementary Table 8 and 
Supplementary Table 9). The effect of indication on access and non-access site bleeding is 
shown in Supplementary Table 10, Supplementary Figure 3 and Supplementary Figure 4.  
For access site- bleeding there was a similar bleeding rates across the indications but for non-
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access site bleeding there was much higher mortality for STEMI (RR 4.42 95% CI 1.77-
11.06) compared to NSTEMI (RR 2.45 95% CI 1.48-4.05).  
 
Discussion 
 Major bleeding complications are one of the most common complications following 
PCI and are independently associated with increased risk of morbidity and mortality1. The 
present analysis of 25 studies involving 2,384,458 subjects is the largest to describing the 
anatomic origin of bleeding after PCI and its prognostic impact. Our analysis suggests that 
the prognostic impact of bleeding complications on mortality depends on the anatomical 
source, with relative risks for mortality varying from 1.6-22.7 fold, with the greatest impact 
on mortality associated with intra-cranial bleeds. Finally, our analysis suggests that non-
access site related bleeding complications have a similar prevalence to those derived from the 
access site (10.2% vs 11.2 %), but are associated with a significantly worse prognosis. 
 Previous studies have reported conflicting data regarding prognostic impact of access 
site related bleeding complications, with studies suggesting either no prognostic impact,5 a 
prognostic impact in only severe bleeds but not mild to moderate bleeds7 or associated with 
increased risk of mortality or cardiovascular events.2, 4, 6, 7, 20 In contrast, previous studies 
have consistently shown a relationship between non-access site related bleeding 
complications and mortality outcomes.2, 4-7, 20 Our analysis suggests that non-access site 
related bleeding complications have a significantly greater impact on mortality (RR 4.06 95% 
CI 3.21-5.14) compared to access site related bleeding complications (RR 1.71 95% CI 1.37-
2.13), which is likely to be multi-factorial in origin. 
 Analysis of the SYNERGY study 7, illustrated that non-access site bleeds accounted 
for 65% of GUSTO severe bleeds whilst only accounting for 41% of GUSTO mild to 
moderate bleeding events whilst the majority of access site bleeding complications were 
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GUSTO mild to moderate bleeds. The prognostic impact of bleeds is related to the severity of 
the bleeding complication,1 hence the greater proportion of non-access site bleeds in the 
GUSTO severe group in this study, may partly explain the greater prognostic impact of non-
access site bleeds on outcomes. Similarly in the study of Ndrepepa6 more severe BARC class 
3 and 4 bleeds were more likely to occur from non-access site compared to access site 
sources.  
 Systemic bleeding events are more likely to occur in older patients with a greater 
burden of co-morbid conditions and a more adverse cardiovascular risk profile than in those 
patients who sustain access site bleeds,6, 7 and adjustment for the comorbid conditions cannot 
fully account for unmeasured confounders. Furthermore, the occurrence of non-access site 
bleeding in patients may not only be a sign of poorer health than in those who sustain an 
access site related bleed but may also have a greater impact in these patients because of their 
compromised health at the time of the bleed. 
  Our analysis suggests that the prevalence of access and non-access site related 
bleeding complications are similar. Access site related major bleeding complications occur 
mainly in PCI procedures undertaken through the femoral artery,30, 31 which has been the 
major driver for transradial access site adoption as a default access site for PCI in many 
European and North American centres because of its association with lower mortality32-34 
through a reduction of such access site related major bleeding complications.30, 34, 35 The 
magnitude of mortality reduction associated with radial artery access site adoption during 
PCI appears to be associated with baseline bleeding risk, with the greatest reductions in 
mortality associated with adoption of the radial access site found in those patients at highest 
risk from baseline bleeding complications.34 
 Our analysis suggests that whilst the prevalence of access site and non-access site 
bleeding complications are similar, rapidly evolving practice in interventional cardiology 
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means that this is likely to change, with recent studies reporting significant changes in access 
site practice from a national perspective over time with more widespread adoption of radial 
access in contemporary PCI procedures in both European and North American national 
registry datasets.32, 36-38 The development of the radial access site as the predominant access 
site choice in many countries such as the UK36 will serve to decrease the prevalence of access 
site related complications, with non-access site bleeding complications representing the most 
common bleeding complication. Changes in anti-platelet therapy towards more potent anti-
platelet therapies whilst reducing ischemic events may increase the propensity towards major 
bleeding complications. For example, in the TRITON TIMI-38 trial 39, use of prasugrel was 
associated with a 30% increase in non-CABG related TIMI major bleeding compared to that 
seen in the clopidogrel arm whilst in the PLATO trial ticagralor use was associated with a 
25% increase non-CABG related TIMI major bleeding.40 Similarly, anti-coagulant choice is 
an important determinant of access and non-access site bleeding complications. Changes in 
anticoagulant practice from heparin and glycoprotein IIb/IIIa regimes to bivalirudin have 
been demonstrated to be associated with reductions in major bleeding and mortality,41, 42 with 
a recent analysis of the NCDR dataset suggesting that changes in anticoagulation strategies 
over time contributed to approximately 50% of the annual reduction in bleeding observed in 
ACS and elective PCI43 with more aggressive anti-coagulant regimes associated with 
significant increases in bleeding complications observed in many of the studies included in 
this meta-analysis (Supplementary Table 9) 
 National datasets have reported significant changes in both access site and non-access 
bleeding complications over a 5-year period from 2005-2009 in procedures undertaken in 
different settings. In elective and UA/NSTEMI PCI, reductions in access site bleeding 
complications have been reported. In contrast, whilst the incidence of non-access site 
bleeding complications have remained constant in both the elective and NSTEMI setting they 
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have increased in the STEMI setting.43 This is likely to represent a complex balance between 
evolving access site practice and use of pharmacological strategies associated with reduced 
bleeding risk, offset by changes in patients demographics such increasing patient age and co-
morbid conditions, increasingly potent anti-platelet therapy as well as a move from elective 
PCI to ACS indications over time which serves to increase baseline bleeding risk of the 
cohorts undergoing PCI procedures. 
 Our meta-analysis has a number of potential limitations. Firstly, studies included in 
this meta-analysis have used different definitions of bleeding that will impact both on the 
reported prevalence of the bleeding complication and it’s prognostic impact.1 Secondly, 
whilst we have shown that the prognostic impact of non-access site bleeds is greater than that 
of access site bleeds; it is unclear whether this is driven by the magnitude of the bleeding 
event. Only 2 studies that have studied the prognostic impact of access vs non access site 
bleeds have adjusted for either measures of, or surrogates for the magnitude of bleeding4, 5 
(Supplementary Table 5). Verheugt et al4 adjusted for haemoglobin values amongst other co-
variates in their statistical models and showed that access site bleeds were independently 
associated with 1-year mortality with an adjusted HR of 1.82 (1.17-2.83) and non-access site 
bleeds with an adjusted HR of 3.94 (3.07-5.15). Similarly, Vranckx et al.5 adjusted for 
haemoglobin levels and blood transfusion and demonstrated that the prognostic impact of a 
non-access site bleed (for the composite endpoint of 12 month Death or AMI) adjusted HR 
2.66 (1.21-5.8) was greater than for an access site bleed adjusted HR 0.74 (0.16-3.4). These 
findings would suggest that even after adjustment for the size of the bleed, non-access site 
bleeds have a greater impact on prognosis than for access site bleeds. Thirdly, the studies 
analyzed are a heterogeneous group of studies, containing cohorts of clinical different 
demographics, undergoing PCI for different indications, treated with different anti-platelet 
regimens and anti-coagulants and differing access site practice. Whilst we used multivariate-
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adjusted or propensity matched risk estimates where available in this analysis, the potential 
for unmeasured confounders that will impact on outcomes remains. Finally, the majority of 
the studies analyzed in this current analysis are derived from North American cohorts, where 
adoption of radial access is still in its infancy outside of a few specialist transradial centers 
with only around 10% of cases undertaken through the radial artery nationally44 that may 
contribute to the high prevalence of access site bleeding complications reported in this 
analysis. 
 In conclusion, the present analysis is the most comprehensive review of the varying 
anatomic origins of bleeding after PCI and their prognostic impact. Our current analysis of 25 
studies involving 2,384,458 subjects confirms that site-specific bleeding complications 
following PCI, irrespective of the anatomical source of bleeding, are independently 
associated with an increased risk of mortality and that the prognostic impact of bleeding 
complications on mortality depends on the anatomical source. Finally, our analysis suggests 
that non-access site related bleeding complications have a similar prevalence to those derived 
from the access site (10.2% vs 11.2%), but are associated with a significantly worse 
prognosis. Clinicians should minimize the risk of peri-procedural bleeding complications 
irrespective of access site adopted during PCI through the use of bleeding avoidance 
strategies such as the use of anti-coagulants associated with reduced bleeding risk, use of 
proton pump inhibitors to reduce the risk of GI bleeding complications in those patients at 
risk, optimal femoral access site practice such as micro-puncture techniques utilizing 
fluoroscopic or ultrasound guidance for femoral access and utilization of the transradial 
access site approach for PCI, particularly in patients at high risk of bleeding complications. 
Particular efforts should be made through careful consideration of pharmacological strategies 
to reduce non-access site bleeding complications since they have the greatest prognostic 
impact. 
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Table 1: Study design, year of study, country of origin and participant inclusion criteria 
Study ID Design Date of study No. of centers Country Inclusion criteria 
Abbas 2005 Post hoc analysis of 
randomized controlled trials. 
Jun 1990 to Mar 
1999. 
Multicenter. International. Participants had PCI for AMI and were enrolled in the PAMI-1, 
PAMI-2, NoSOS, Stent-PAMI and Air-PAMI trials. 
Amabile 2012 Retrospective cohort study. Jan 2006 to Oct 2008. Single center. France. Participants had STEMI treated with PCI. 
Chhatriwalla 
2013 
Cohort study. 2004 to 2011 1500 centers. USA. Participants had PCI. 
Chin 2007 Retrospective case-control 
study. 
Jan 1998 to Jan 2005. Single center. Australia. Participants had PCI for stable angina and acute coronary 
syndromes. 
Chua 2011 Retrospective cohort study. Jan 2001 to Dec 2006. Single center. Taiwan. Participants had STEMI treated with PCI. 
Doyle 2008 Prospective cohort study. 
 
1994 to 2005. Single center. USA. Participants had transfemoral PCI and were included on the 
Mayo Clinic PCI database. 
Ellis 2006 Retrospective cohort study. 
 
1992 to 2003. Single center. USA. Participants had PCI at the Cleveland clinic. 
Ergelen 2010 Retrospective cohort study. Oct 2003 to Mar 
2008. 
Single center. Turkey. Participants had STEMI treated with coronary angiography. 
Farouque 2005 Retrospective cohort study. Jan 2000 to Jan 2004. Single center. USA. Participants had PCI. 
Gaglia 2010 Prospectively cohort study. 
 
Jan 2000 to Jan 2010. Single center. USA. Participants had PCI. 
Matic 2013 Prospective cohort study. Aug 2009 to Jan 
2011. 
Single center. Serbia. Participants had STEMI treated with PCI. 
Ndrepepa 2013 Post hoc analysis of 
randomized control trials. 
Jun 2000 to May 
2011. 
Multicenter. International. Participants were part of 7 randomized clinical trials (ISAR-
REACT, ISAR-SWEET, ISAR-SMART-2, ISAR-REACT-2, 
ISAR-REACT-3, ISAR-REACT-3A, ISAR-REACT-4). 
Nikolsky 2009 Post hoc analysis of 
randomized control trial. 
Aug 2003 to Dec 
2005. 
450 centers. International. Participants were part of ACUITY trial and were randomized to 
1 of 3 antithrombotic regimens prior to angiography. 
Pres 2010 Retrospective cohort study. Unclear. Unclear. 
 
Poland. Participants with STEMI treated with PCI. 
Shivaraju 2011 Retrospective cohort study. 1998 to 2006. 1050 centers. USA. Participants were part of National Inpatient Sample with PCI 
for AMI or CAD diagnoses. 
Song 2007 Retrospective cohort study. Unclear. Unclear. China. Participants had PCI. 
Stathoupoulos 
2013 
Prospective cohort study. 1999 to 2006. Single center. USA. Participants had PCI and coronary perforation. 
Thiele 2010 Retrospective cohort study. 
 
Unclear. Unclear. Germany. Participants had STEMI treated with PCI. 
Thimarchi 2010 Prospective cohort study. Oct 2002 to Dec 
2007. 
Multicenter. USA. Participants were in Blue Cross Blue Shield of Michigan 
Cardiovascular Consortium Registry who had PCI. 
Vavalle 2013 Post hoc analysis of 
randomized controlled trial. 
Aug 2001 to Dec 
2003. 
Multicenter. International. Participants were in SYNERGY trial which randomized 
patients with NSTEMI ACS to enoxaparin or unfractionated 
heparin. 
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Verheugt 2011 Post hoc analysis of 
randomized controlled trial. 
Unclear. Multicenter. International. Participants had PCI who were a part of REPLACE-2, 
ACUITY and HORIZONS-AMI trials. 
Vranckx 2012 Post hoc analysis of 
randomized controlled trial. 
Unclear. 
 
16 centers. Italy, Argentina 
and Spain. 
Participants had STEMI which was treated with PCI and were 
included in MULTISTRATEGY study. 
White 2010 Post hoc analysis of 
randomized controlled trial. 
Recruited Jan 2004 to 
Dec 2004. 
124 centers. International, 9 
countries. 
Participants were in STEEPLE trial who were ≥17 years of age 
and scheduled to undergo elective PCI with a femoral approach. 
Yatskar 2007 Cohort study. Jul 2007 to Mar 2002. 19 centers. USA. Participants were in National Heart, Lung and Blood Institute 
Dynamic Registry who underwent PCI. 
Yeh 2013 Cohort study. 2008 1051 centers. USA. Participants had acute myocardial infarction who had PCI. 
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Table 2: Timing of bleeding, definition of major bleeding, follow up  
Study ID Type of 
bleeding 
Time of 
bleeding 
No. in bleeding 
group 
Results 
Abbas 2005 GI bleed. In-hospital. 71 In-hospital: death aOR 3.98 (1.40-11.3) 
6 month: death 10/71 vs 139/3039, MACE 15/71 vs 424/3039. 
Amabile 2012 Intramyocardial 
bleed. 
In-hospital. 11 Adverse event: aHR 2.8 (1.2-6.8). 
Chhatriwalla 
2013 
Access site and 
non-access site 
bleed. 
In-hospital. Access site bleed 
30346 2.73%, 
non-access site 
25732 8.25%. 
Access site bleed and mortality: 2.73% vs 1.87%, risk difference 0.86% (0.66-1.05%). 
Non-access site bleed and mortality: 8.25% vs 1.87%, risk difference 6.39% (6.04%-6.73%)). 
Chin 2007 GI bleed. Within 30 
days of PCI. 
 
67 Mortality at 30 days: 8 (11.9%) vs 1 (0.5%) and 180 days: 9 (13.4%) vs 1 (0.5%). 
Chua 2011 GI bleed. In-hospital, 
about one 
week 
18 Crude mortality in-hospital 8/18 bleed vs. 43/501 non-bleed 
Doyle 2008 Femoral bleed, 
retroperitoneal 
bleed. 
Within 30 
days. 
Femoral 
bleed/hematoma 
855, 
retroperitoneal 
65 
Mortality at 30 days: femoral bleed HR 9.96 (6.94-14.3). 
Mortality at 30 days: retroperitoneal bleed HR 43.8 (16.4-75.1). 
 
 
Ellis 2006 Retroperitoneal 
bleed. 
In-hospital. 163 Crude mortality: 17/163 (10.4%) vs 198/28215 (0.7%). 
Ergelen 2010 GI bleed. In-hospital. 27 Crude mortality in-hospital: 5/27 (18.5%) vs 73/2514 (2.9%). 
Farouque 2005 Retroperitoneal 
bleed. 
In-hospital. 26 Crude mortality in-hospital with retroperitoneal bleed: 1/26 vs 1/50. 
Gaglia 2010 GI bleed. In-hospital. 147 Mortality at 30 days: GI bleed no shock aHR 5.82 (2.56-13.2) and GI bleed shock aHR 10.4 
(3.64-29.8),  
Crude mortality at 1 year: 17.9% vs 4.9%. 
MACE 1 year aHR 1.23 (0.55-2.79). 
 
Matic 2013 Access site and 
non-access site 
bleed. 
In-hospital. Access site 
bleed: 67, non-
access site bleed 
51. 
Mortality at 1 year access site bleeding vs BARC class 0+1: HR 1.88 (1.01-3.52). 
Mortality at 1 year non-access site bleeding vs BARC class 0+1: HR 6.80 (3.81-12.14). 
Ndrepepa 2013 Access site, 
non-access site, 
retroperitoneal, 
gastrointestinal, 
pericardial, 
30 days. Access site 905, 
non-access site 
605. 
Mortality at 1 year with access site bleeding vs no bleeding: aHR 1.72 (1.19-2.47). 
Mortality at 1 year with non-access site bleeding vs no bleeding: aHR 2.78 (2.00-3.86). 
Death with retroperitoneal bleeding: 1/25 vs 310/12,670. 
Death with gastrointestinal bleeding: 11/152 vs 310/12,670 
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intracranial 
bleed. 
Death with pericardial bleeding: 10/53 vs 310/12,670 
Death with intracranial bleeding: 5/9 vs 310/12,670 
Nikolsky 2009 GI bleed. 30 days. 
. 
178 Mortality at 30 day: crude rate 9.5% vs 1.4%, aHR 4.87 (IQR 2.61-9.08), composite ischemia at 
30 day: crude rate 19.8% vs 7.5%, aHR 1.94 (IQR 1.14-3.30). 
Mortality at 1 year: crude rate 21.9% vs 3.9%, composite ischemia at 1 year: 34.7% vs 16.3%. 
1-year all-cause mortality: HR 3.97 (IQR  2.64-5.99). 
Pres 2010 GI bleed. In-hospital. 78 Mortality in-hospital: aOR 1.27 (1.04-1.56). 
Mortality 3 year: aHR 1.58 (1.07-2.33). 
Shivaraju 2011 GI bleed. In-hospital. 12694 Mortality in-hospital: aOR 4.70 (4.23-5.23). 
 
Song 2007 GI bleed. In-hospital 21 Crude MACE: 23% vs 9.3%. 
Stathoupoulos 
2013 
Cardiac 
tamponade. 
In-hospital. 26 Mortality in-hospital: 7.7% vs 4.3%.  
Long term mortality: OR 3.3 (1.01-10.65). 
Thiele 2010 Intramyocardial 
bleed. 
In-hospital. 143 Crude MACE: 13% vs 12%. 
Crude mortality 5% vs 4%. 
Thimarchi 
2010 
Retroperitoneal 
hematoma. 
In-hospital. 482 In-hospital death: 28/482 vs 1868/111858. 
In-hospital MI: 32/482 vs 1197/111858. 
In-hospital MACE: 65/482 vs 4676/111858. 
Vavalle 2013 Access site and 
non-access site 
bleed. 
In-hospital. Access site 
bleed: 1830. 
Non-access site 
bleed: 3070. 
Death/MI at 6 months access site bleed: severe HR 3.57 (2.35-5.40), mild/moderate HR 0.96 
(0.82-1.2). 
Death/MI at 6 months: severe surgical bleed HR 5.27 (3.80-7.29), severe systemic bleeds HR 
4.48 (2.98-6.72), mild/moderate surgical bleed HR 2.52 (2.16-2.94), mild/moderate systemic 
bleed HR 1.40 (1.16-1.69), mild/moderate superficial bleed HR 1.17 (0.97-1.40). 
Verheugt 2011 Access site and 
non-access site 
bleed. 
30 days. Access site 357, 
non-access site 
142 
Mortality at 1 year: access site bleed vs no bleed: aHR 1.82 (1.17-2.83). 
Mortality at 1 year: non-access site bleed vs no bleed: aHR 3.94 (3.07-5.15). 
Vranckx 2012 Access site and 
non-access site 
bleed. 
Within 30 
days of PCI 
NA Access site bleed and 12 month death/MI: aHR 0.74 (0.16-3.4).  
Non access site bleed and 12 month death/MI: aHR 2.66 (1.21-5.8) 
 
White 2010 Femoral 
hematoma ≥5 
cm. 
Within 30 
days of PCI. 
103 Mortality at 1 year: 0/103 vs 55/3229. 
MACE at 30 days: 6/103 vs 190/3229. 
Yatskar 2007 Access site 
bleeding 
requiring 
transfusion. 
Unclear. 120 In-hospital mortality: aOR 3.59 (1.66-7.77). 
1 year mortality: aOR 1.65 (1.01-2.70). 
Yeh 2013 GI bleed. Mortality. 29010 Mortality: aOR 1.177 (1.111-1.247). 
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Table 3: Site specific bleeding and risk of morality and major adverse cardiovascular events 
Type of bleeding Studies Participants 
with bleed 
Participants 
with no bleed 
Risk of adverse outcome 
Intramyocardial15, 25 2 154 276 MACE: RR 1.65 (0.66-4.13) 
Pericardial6 1 53 12,670 Mortality: RR 7.71 (4.37-13.61) 
Cardiac tamponade with coronary 
perforation24 
1 26 47 Mortality: RR 3.30 (1.02-10.72) 
Intramyocardial, pericardial or 
cardiac tamponade 6, 15, 24, 25 
4 233 12,993 Adverse outcomes: RR 2.96 (1.07-8.17) 
Gastrointestinal6, 10, 14, 16-19, 21, 22, 29 9 42,442 1,875,483 Mortality:  
Unadjusted: RR 6.39 (4.58-8.91) 
Adjusted: RR 2.78 (1.25-6.18) 
Gastrointestinal14, 19, 21, 23 4 417 39,432 MACE: 
Unadjusted RR: 2.25 (1.66-3.05) 
Adjusted RR: 1.23 (0.55-3.05) 
Retroperitoneal6, 8, 9, 11, 26 5 696 152,793 Mortality: RR 5.87 (1.63-21.12)  
Intracranial6 1 9 12,670 Mortality: RR 22.71 (12.53-41.15) 
Femoral8, 27 2 103 3,239 Mortality: RR 2.17 (0.07-69.22) 
Access site 2, 4-7, 20, 28 5 
7 
31,795 
33,677 
261,676 
267,446 
Mortality: RR 1.71 (1.37-2.13)  
Adverse outcomes: RR 1.65 (1.37-1.99) 
Non-access site2, 4-7, 20 4 
6 
26,530 
29,652 
255,140 
261,548 
Mortality: RR 4.06 (3.21-5.14) 
Adverse outcomes: RR 3.70 (2.92-4.69) 
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Figures legends 
Figure 1: Risk of mortality with access and non-access site bleeding 
Figure 2: Risk of mortality with GI bleed 
Figure 3: Risk of MACE with GI bleed 
Figure 4: Risk of mortality with retroperitoneal bleed 
Figure 5: Risk of adverse outcome with intramyocardial bleed, pericardial bleed or cardiac tamponade 
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Figure 1: Risk of mortality with access and non-access site bleeding 
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Figure 2: Risk of mortality with GI bleed 
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Figure 3: Risk of MACE with GI bleed 
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Figure 4: Risk of mortality with retroperitoneal bleed 
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Figure 5: Risk of adverse outcome with intramyocardial bleed, pericardial bleed or cardiac 
tamponade 
 
  
 
